Preliminary Programme

Multidisciplinary Pre-Congress Day

11:00 – 13:00 JOINT SESSION (with Czech interpretation)
11:00 – 11:15 Welcome and Introduction
11:15 – 11:35 Nurses Presentation:
The ideal and the real role of the haemophilia nurse – Czech experience
V Cepelakova
11:35 – 11:55 Physiotherapists Presentation:
Important aspects of paediatric health to become a healthy adult
M Katzerova
11:55 – 12:15 Psychosocial Professionals Presentation:
Preventing psychosomatic consequences in bleeding disorders
P Buckova
12:15 – 13:00 Joint Case Discussion and Q&A All disciplines
13:00 – 14:00 Lunch

14:00 – 17:00 NURSES SESSION (with Czech interpretation)
14:00 – 15:30 Session 1 – Explaining complex medical concepts to patients living with bleeding disorders
14:00 – 14:20 What should nurses know regarding the coagulation cascade and new treatments? M Albisetti
14:20 – 14:35 Explaining difficult issues to patients M Nolan
14:35 – 15:05 Health literacy S Sørensen
15:05 – 15:15 Q&A
15:15 – 15:30 Break
15:30 – 16:15 Session 2 – Innovative Approaches for Care Delivery
15:30 – 15:45 T-GROW Model of Communication M Friberg Birkedal
15:45 – 16:00 Distant care S Grønhaug
16:00 – 16:15 Eight years of nurse-led clinics M Kavanagh
16:15 – 16:30 Break
16:30 – 17:00 Session 3 – Is there a future for haemophilia nursing?
16:30 – 16:40 No, there will be no future M Bedford
16:40 – 16:50 Yes, there is a future K Juusola
16:50 – 17:00 The audience decides

14:00 – 17:00 PHYSIOTHERAPISTS SESSION (with Czech interpretation)
14:00 – 15:00 Session 1
14:00 – 14:45 Basics of radiological assessment useful for PTs H Marmery
14:45 – 15:00 Q&A
15:00 – 16:00 Workshops*
15:00 – 15:45 Workshop 1: Point of Care Ultrasound M Timmer
D Stephensen
 15:00 – 15:45 Workshop 2: Strengthening strategies in paediatrics according to DNS K Ptakova
15:45 – 16:00 Q&A
16:00 – 17:00 Workshops*
16:00 – 16:45 Workshop 1: Point of Care Ultrasound M Timmer
D Stephensen
 16:00 – 16:45 Workshop 2: Strengthening strategies in paediatrics according to DNS K Ptakova
16:45 – 17:00 Q&A

*To encourage interaction during the Workshops, participants will be split into two groups. Half of the group will first attend Workshop 1, then Workshop 2 and the other half of the group will attend the Workshops in the reverse order.

 

14:00 – 17:00 PSYCHOSOCIAL PROFESSIONALS SESSION (with Czech interpretation)
14:00 – 15:00 Session 1
14:00 – 14:45 Differences between the present and future through the new treatments G Golan
14:45 – 15:00 Q&A
15:00 – 16:00 Session 2
15:00 – 15:45 The effect of bleeding disorders on the wider family and caregivers C Burgess
15:45 – 16:00 Q&A
16:00 – 17:00 Session 3
16:00 – 16:45 The effect of growing up with haemophilia into adulthood A Torres-Ortuño
16:45 – 17:00 Q&A
17:00 – 18:00 Networking Reception

IMPORTANT: Pre-Congress Day registration requires a separate, additional fee and is not automatically included in the registration for the main congress.

EAHAD Congress

Multidisciplinary Educational Session Chairs:
C Hermans
R Klamroth
09:30 – 11:00 Managing comorbidities in older people with haemophilia C Hermans
R Klamroth
F Sayers
N Uitslager
11:00 – 11:30 Coffee Break
SATELLITE SYMPOSIA Company Room
11:30 – 12:45 Satellite Symposium 1 F. Hoffman-La Roche Congress Hall
Satellite Symposium 2 Shire Forum Hall
12:45 – 13:45 Lunch Break
13:45 – 15:00 Satellite Symposium 3 Biomarin Congress Hall
Satellite Symposium 4 Octapharma AG Forum Hall
Satellite Symposium 5 Novo Nordisk Healthcare AG South Hall
15:00 – 15:30 Coffee Break
15:30 – 16:45 Satellite Symposium 6 Sobi Congress Hall
Satellite Symposium 7 Bayer Forum Hall
Satellite Symposium 8 Pfizer South Hall
16:45 – 17:15 Coffee Break
17:15 – 18:30 Satellite Symposium 9 CSL Behring Congress Hall
Satellite Symposium 10 Spark Therapeutics Forum Hall
Satellite Symposium 11 Grifols South Hall
18:30 – 19:30 Welcome Reception

EAHAD Congress

08:45 – 09:00 WELCOME AND INTRODUCTION J Blatny
09:00 – 10:30 SESSION 1: Gene therapy in haemophilia Chairs:
W Miesbach
A Batorova
09:00 – 09:30 Current status of the gene therapy in haemophilia A and haemophilia B – 2019 update J Pasi
09:30 – 10:00 How (much) can we pay for gene therapy in haemophilia? P Cortesi
10:00 – 10:30 How can a patient choose between all of the available therapies? D Noone
10:30 – 11:00 Coffee Break/Poster Viewing
11:00 – 12:30 SESSION 2: Inhibitors – the major challenge in haemophilia treatment Chairs:
H Chambost
E Zapotocka
11:00 – 11:30 Why and how do inhibitors develop in haemophilia A and B? D Matino
11:30 – 12:00 What is the optimal treatment for a newly diagnosed PUP? K Fijnvandraat
12:00 – 12:30 Novel agents for treatment of haemophilia with inhibitors A Tiede
12:30 – 13:30 Lunch Break/Poster Viewing/EAHAD Annual General Meeting
13:30 – 15:00 SESSION 3: Rare bleeding disorders Chairs:
V Jimenez-Yuste
M Penka
13:30 – 14:00 TFPI and Factor V short E Castoldi
14:00 – 14:30 FVII deficiency – what does it mean for the patient and the treater? A Batorova
14:30 – 15:00 Gene therapy for inherited bleeding disorders other than haemophilia A and B E Tuddenham
15:00 – 15:30 Coffee Break/Poster Viewing
15:30 – 16:45 SESSION 4: Clinical registries and Real World Data Chairs:
G Dolan
Z Cermakova
15:30 – 16:00 The benefit of a national registry J Blatny
16:00 – 16:30 The advantages and disadvantages of registries F Rosendaal
16:30 – 16:45 Break
16:45 – 17:45 SESSION 5: Acquired bleeding disorders Chairs:
R Lassila
J Gumulec
16:45 – 17:15 The coagulopathy of trauma H Schöchl
17:15 – 17:45 Acquired von Willebrand disease J Eikenboom
20:00 – 00:00 Networking Evening

EAHAD Congress

07:30 – 08:30 MORNING CLINICAL CASES Chairs:
F Peyvandi
M Makris
4 x 15 min Clinical case presentations
08:30 – 10:00 SESSION 6: SLAM Chairs:
R Klamroth
K Fijnvandraat
P Dulicek
OR03 Unique inflammatory signature in hemophilic arthropathy: epigenetic changes due to interaction between blood and fibroblast-like synoviocytes S Mignot
 OR04 Psycho-social determinants on caregivers’ burden of children with haemophilia (results of the BBC study) K Khair
 OR05 Until what age should we worry about inhibitors? New data from the Pednet registry on 1038 pups with severe hemophilia a followed from the first until over 1000 exposure days M van den Berg
 OR06 Improved survival of patients with hemophilia in the Netherlands in the 21st century S Hassan
 OR07 Changing paradigma in turkey: plasma derived fviii products have mostly preferred for pup patients in severe hemophilia-A for last two years K Kavakli
 OR08 Intracranial hemorrhage in hemophilia – a systematic review A Zwagemaker
 OR09 The web-accessible population pharmacokinetics service–hemophilia (wapps-hemo) contribution to tailoring treatment in children: examples for hemophilia A and B C Hoi Ting Yeung
 OR10 Phase 2b trial of amt-061 (aav5-padua hfix): translation into humans of an enhanced gene transfer vector for adults with severe or moderate-severe hemophilia B A Von Drygalski
 OR11 Phase 2/3 trial of subcutaneous engineered fviia marzeptacog alfa (activated) in hemophilia a or b with inhibitors: pharmacokinetics, pharmacodynamics, efficacy and safety H Levy
 OR12 Safety analysis of concomitant use of rfviia and emicizumab in congenital haemophilia a with inhibitors: experience from the haven clinical programme S Seremetis
10:00 – 10:30 Coffee Break/Poster Viewing
10:30 – 11:30 SESSION 7: Monitoring the treatment of haemophilia Chairs:
M Makris
I Hrachovinova
10:30 – 11:00 Monitoring joint damage in black and white W Foppen
11:00 – 11:30 Laboratory monitoring of novel therapies C Novembrino
11:30 – 12:00 AROSENIUS LECTURE 2019 Chairs:
J Blatny
P Petrini
Haemophilia in Africa P de Moerloose
12:00 – 12:30 Break
12:30 – 13:15 POSTER AND RESEARCH AWARDS Chairs:
M Makris
J Blatny
12:30 – 13:00 Reports from 2017 Research Grant winners J Boender
R Palla
13:00 – 13:15 Award presentations
13:15 – 14:15 SESSION 8: HOT TOPICS Chairs:
M Makris
J Blatny
 OR13 Bivv001 – a novel, vwf-independent, extended half-life fviii therapy: first-in-human safety, tolerability, and pharmacokinetics J Mannion
 OR14 Incidence of inhibitors in previously untreated patients with severe haemophilia a treated with rfviiifc: the pups a-long study C Königs
 OR15 Surgical procedures in persons with haemophilia a (pwha) without inhibitors receiving emicizumab – experience from the haven 3 study E Santagostino
 OR16 The role of antithrombin lowering in patients with hemophilia: hemostatic control pre- and post-fitusiran dosing interruption J Pasi
14:15 – 14:30 CLOSING REMARKS J Blatny
14:30 – 15:30 Lunch